Profile data is unavailable for this security.
About the company
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
- Revenue in USD (TTM)52.29m
- Net income in USD-134.84m
- Incorporated1995
- Employees405.00
- LocationSangamo Therapeutics Inc501 Canal Blvd.RICHMOND 94084United StatesUSA
- Phone+1 (510) 970-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.sangamo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | 24.40m | -197.03m | 490.20m | 255.00 | -- | 0.9636 | -- | 20.09 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 492.00m | 116.00 | -- | -- | -- | 19.28 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Grail Inc | 109.74m | -2.88bn | 494.30m | 1.37k | -- | 0.1834 | -- | 4.50 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Alector Inc | 61.51m | -158.41m | 501.90m | 241.00 | -- | 4.22 | -- | 8.16 | -1.71 | -1.71 | 0.6607 | 1.21 | 0.1035 | -- | -- | 252,082.00 | -26.66 | -20.00 | -35.58 | -23.81 | -- | -- | -257.54 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Larimar Therapeutics Inc | 0.00 | -64.77m | 506.62m | 42.00 | -- | 2.55 | -- | -- | -1.15 | -1.15 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -40.11 | -42.22 | -43.16 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Sangamo Therapeutics Inc | 52.29m | -134.84m | 508.06m | 405.00 | -- | 13.01 | -- | 9.72 | -0.7079 | -0.7079 | 0.2696 | 0.1876 | 0.316 | -- | 8.98 | 129,113.60 | -81.48 | -26.09 | -112.69 | -31.04 | -- | -- | -257.86 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Korro Bio Inc | 0.00 | -92.22m | 511.53m | 92.00 | -- | 2.58 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| SS Innovations International Inc | 14.41m | -23.68m | 512.22m | 239.00 | -- | 30.16 | -- | 35.55 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Aura Biosciences Inc | 0.00 | -80.69m | 512.43m | 88.00 | -- | 2.68 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 512.91m | 150.00 | -- | 2.61 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Neurogene Inc | 925.00k | -55.44m | 515.33m | 91.00 | -- | 3.32 | -- | 557.11 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 518.67m | 180.00 | -- | 1.98 | -- | 3.23 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Regenxbio Inc | 84.33m | -238.81m | 528.65m | 344.00 | -- | 1.75 | -- | 6.27 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Monte Rosa Therapeutics Inc | 14.98m | -119.39m | 529.65m | 103.00 | -- | 2.58 | -- | 35.37 | -1.83 | -1.83 | 0.2215 | 3.35 | 0.0528 | -- | 33.69 | 112,594.00 | -42.10 | -- | -47.48 | -- | -- | -- | -797.26 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Sangamo Therapeutics Inc's reporting currency: US Dollar USD
30.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wasatch Advisors LPas of 30 Jun 2024 | 20.09m | 9.65% |
| Armistice Capital LLCas of 30 Jun 2024 | 14.06m | 6.75% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.60m | 4.61% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 4.56m | 2.19% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 4.13m | 1.98% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.12m | 1.50% |
| Jacobs Levy Equity Management, Inc.as of 30 Jun 2024 | 2.95m | 1.42% |
| Millennium Management LLCas of 30 Jun 2024 | 2.41m | 1.16% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.87m | 0.90% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 1.58m | 0.76% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
